Factors Increasing Recurrence of Hepatocellular Carcinoma Post Liver Transplant

Posted by:

Liver transplant has been used to achieve an oncologic ‘cure’ for unresectable hepatocellular carcinoma (HCC). Despite some excellent outcomes and careful donor selection, a subset of liver-recipients experience a recurrence of HCC post-transplant. Parsia A. Vagefi and his team set out to research the cause of carcinoma recurrence and whether there are identifiable donor-derived factors.

6.5% of recipients (324 transplant recipients) experienced HCC recurrence post-transplant between 2006-2010. The data was statistically significant for an increased risk of HCC recurrence within 4 years post-transplant when the donors were aged at least 60 years (11.8% vs. 7.3%; P < .001). Another statistically significant factor for recurrence was when recipients received a liver from nonlocal share distribution (10.6% vs. 7.4%; P = .004).

Applying a multivariate analysis identified transplant recipients carrying a 70% higher risk for HCC recurrence if they received a liver from a donor aged at least 60 years and a 42% increased risk for HCC recurrence if they received a liver from nonlocal share distribution.

Utilizing these donor-derived factors in the selection process for the potential recipients, may improve long-term survival post-transplant, according to Vagefi.

Read article at: http://www.healio.com/hepatology/transplantation/news/online/%7B646639ef-c27c-4b00-8a42-48e36f668bca%7D/older-donor-age-nonlocal-distribution-potentially-increase-hcc-recurrence-after-liver-transplant

Full research article available at: http://onlinelibrary.wiley.com/doi/10.1002/lt.24042/abstract;jsessionid=F9DD7E7D4BDED07D3C3CAD1FECC721CD.f04t02

Image from: http://gastroliver.medicine.ufl.edu/hepatology/for-patients/liver-diseases-treatment/liver-cancer-hcc/



About the Author:

  Related Posts

Add a Comment